| Preclinical efficacy studies in investigator brochures: do they enable risk–benefit assessment? S Wieschowski, WWL Chin, C Federico, S Sievers, J Kimmelman, ... PLoS biology 16 (4), e2004879, 2018 | 69 | 2018 |
| Access policies in biobank research: what criteria do they include and how publicly available are they? A cross-sectional study H Langhof, H Kahrass, S Sievers, D Strech European Journal of Human Genetics 25 (3), 293-300, 2017 | 35 | 2017 |
| Investigator brochures for phase I/II trials lack information on the robustness of preclinical safety studies S Sievers, S Wieschowski, D Strech British Journal of Clinical Pharmacology 87 (7), 2723-2731, 2021 | 12 | 2021 |
| Tracking the timely dissemination of clinical studies D Strech, S Sievers, S Märschenz, N Riedel, S Wieschowski, J Meerpohl Characteristics and impact of 10, 0 | 5 | |
| Tracking the timely dissemination of clinical studies. Characteristics and impact of 10 tracking variables D Strech, S Sievers, S Märschenz, N Riedel, S Wieschowski, J Meerpohl, ... F1000Research 7, 2018 | 4 | 2018 |
